Home Tags Boehringer Ingelheim

Tag: Boehringer Ingelheim

Danbury Mayor Boughton named state DRS commissioner; Delivers farewell address

Mark Boughton, who is in the midst of his record 10th term as the city’s mayor, will begin his new job on Dec. 18.

Boehringer Ingelheim appoints Yew Looi Liew as U.S. Human Pharma president

Liew, who succeeds Jean-Michel Boers, will be responsible for developing BI’s current human pharma portfolio and preparing the organization for future launches.

FDA gives fast track designation to test Jardiance for heart attack...

Test trial results are expected by 2023.

Jean-Michel Boers succeeding Wolfgang Baiker as head of Boehringer Ingelheim U.S.

Boers joined Boehringer Ingelheim in 1998 in Belgium, and came to the U.S. in 2016 as senior vice president of the Specialty Care Franchise; he has led the U.S. Human Pharma business since January 2017.

Ridgefield’s Boehringer Ingelheim launches Global Support Program to fight COVID-19

Among its efforts, Boehringer has made available $6.4 million for financial and in-kind donations for local emergency aid across its markets.

Taking a toll on commuters: Lamont woos politicians and residents on...

The future of the governos’s ambitious 10-year, $21 billion CT2030 plan is very much in doubt, with state Republicans remaining skeptical and several of his fellow Democratic lawmakers hedging their bets as next year’s election looms.

Boehringer Ingelheim, Sanofi targeted in class-action suit over Zantac

According to the lawsuit, “Zantac’s unprecedented sales were possible only because of a deception perpetrated by the drug’s manufacturers on consumers.”

Boehringer gets FDA nod for lung disease treatment

Ofev is now approved in the U.S. and more than 70 countries for the treatment of patients living with idiopathic pulmonary fibrosis.

Boehringer Ingelheim teams with MD Anderson on cancer research center

Boerhinger Ingelheim's Victoria Zazulina said the new center will "transform the treatment landscape for these diseases."

Stamford’s Taylor Design: Local focus, international reach

Hospitals, universities, air freight companies, and even fish farms, are growth sectors for the graphic design firm.

Boehringer Ingelheim acquires Swiss biotech Amal Therapeutics

Amal’s lead vaccine ATP128 is currently being developed for stage IV colorectal cancer and is slated to begin its first-in-human trials later this month.

FDA accepts new diabetes drug application from Boehringer Ingelheim and Eli...

About 30 million Americans have diabetes with more than 7 million undiagnosed.

Boehringer Ingelheim ordered to pay $542K in Pradaxa case

Boehringer could ultimately be ordered to pay twice the jury’s amount, or $1,084,930, in addition to awarding the plaintiff punitive damages.

Boehringer launches first-of-its-kind COPD patient registry

APEX COPD is specifically designed to improve the management of patients with the disease, which affects more than 1 in 20 adults in the U.S.

Boehringer Ingelheim settles litigation over Humira biosimilar

Humira is a medication used to treat Crohn’s disease, psoriasis, ulcerative colitis and several forms of arthritis.